Table 2. Clinical, risk behaviour characteristics as well as perceptions, attitudes and previous monkeypox diagnoses of respondents of the monkeypox vaccine acceptance survey, World Health Organization European Region, 30 July–12 August 2022.
| Characteristic | Sample description | Vaccine acceptancea | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number | %b | Acceptance number |
%c | Hesitancy number |
%c | Refusal number |
%c | No answer/ missing number |
%c | |
| HIV | ||||||||||
| HIV − | 27,585 | 83.8 | 22,538 | 81.7 | 2,467 | 8.9 | 2,303 | 8.3 | 277 | 1.0 |
| HIV + on ART | 3,780 | 11.5 | 3,335 | 88.2 | 209 | 5.5 | 208 | 5.5 | 28 | 0.7 |
| HIV + not on ART | 123 | 0.4 | 92 | 74.8 | 10 | 8.1 | 20 | 16.3 | 1 | 0.8 |
| HIV status unknown | 989 | 3.0 | 709 | 71.7 | 156 | 15.8 | 111 | 11.2 | 13 | 1.3 |
| Prefer not to answer | 339 | 1.0 | 242 | 71.4 | 40 | 11.8 | 37 | 10.9 | 20 | 5.9 |
| Missing | 86 | 0.3 | 64 | 74.4 | 8 | 9.3 | 7 | 8.1 | 7 | 8.1 |
| PrEPd | ||||||||||
| No | 21,526 | 74.2 | 16,827 | 78.2 | 2,364 | 11 | 2,168 | 10.1 | 167 | 0.8 |
| Yes | 7,210 | 24.9 | 6,543 | 90.7 | 275 | 3.8 | 261 | 3.6 | 131 | 1.8 |
| Missing | 263 | 0.9 | 183 | 69.6 | 32 | 12.2 | 29 | 11.0 | 19 | 7.2 |
| STI diagnosis in the last 12 months | ||||||||||
| No | 26,059 | 79.2 | 20,957 | 80.4 | 2,493 | 9.6 | 2,390 | 9.2 | 219 | 0.8 |
| Yes | 6,156 | 18.7 | 5,521 | 89.7 | 308 | 5 | 231 | 3.8 | 96 | 1.6 |
| Unknown | 474 | 1.4 | 356 | 75.1 | 65 | 13.7 | 46 | 9.7 | 7 | 1.5 |
| Prefer not to answer | 111 | 0.3 | 74 | 66.7 | 14 | 12.6 | 12 | 10.8 | 11 | 9.9 |
| Missing | 102 | 0.3 | 72 | 70.6 | 10 | 9.8 | 7 | 6.9 | 13 | 12.7 |
| Engaged in chemsex in last 3 months | ||||||||||
| No | 29,723 | 90.3 | 24,270 | 81.7 | 2,750 | 9.3 | 2,465 | 8.3 | 238 | 0.8 |
| Yes | 2,892 | 8.8 | 2,503 | 86.5 | 123 | 4.3 | 195 | 6.7 | 71 | 2.5 |
| Prefer not to answer | 241 | 0.7 | 178 | 73.9 | 16 | 6.6 | 24 | 10.0 | 23 | 9.5 |
| Missing | 46 | 0.1 | 29 | 63.0 | 1 | 2.2 | 2 | 4.3 | 14 | 30.4 |
| Perception of personal risk of MPX infection | ||||||||||
| Not worried | 4,211 | 12.8 | 2,087 | 49.6 | 630 | 15 | 1,462 | 34.7 | 32 | 0.8 |
| Slightly worried | 7,277 | 22.1 | 5,696 | 78.3 | 907 | 12.5 | 613 | 8.4 | 61 | 0.8 |
| Moderately worried | 7,232 | 22.0 | 6,221 | 86.0 | 658 | 9.1 | 295 | 4.1 | 58 | 0.8 |
| Worried | 8,269 | 25.1 | 7,627 | 92.2 | 390 | 4.7 | 157 | 1.9 | 95 | 1.1 |
| Very worried | 5,243 | 15.9 | 5,004 | 95.4 | 143 | 2.7 | 78 | 1.5 | 18 | 0.3 |
| I don’t know | 630 | 1.9 | 330 | 52.4 | 161 | 25.6 | 80 | 12.7 | 59 | 9.4 |
| Missing | 40 | 0.1 | 15 | 37.5 | 1 | 2.5 | 1 | 2.5 | 23 | 57.5 |
| Perception of MPX severity | ||||||||||
| Not severe | 1,282 | 3.9 | 527 | 41.1 | 118 | 9.2 | 625 | 48.8 | 12 | 0.9 |
| Slightly severe | 3,874 | 11.8 | 2,812 | 72.6 | 443 | 11.4 | 586 | 15.1 | 33 | 0.9 |
| Moderately severe | 10,170 | 30.9 | 8,495 | 83.5 | 991 | 9.7 | 634 | 6.2 | 50 | 0.5 |
| Severe | 10,373 | 31.5 | 9,275 | 89.4 | 634 | 6.1 | 335 | 3.2 | 129 | 1.2 |
| Very severe | 4,586 | 13.9 | 4,275 | 93.2 | 171 | 3.7 | 106 | 2.3 | 34 | 0.7 |
| I don’t know | 2,581 | 7.8 | 1585 | 61.4 | 531 | 20.6 | 398 | 15.4 | 67 | 2.6 |
| Missing | 36 | 0.1 | 11 | 30.6 | 2 | 5.6 | 2 | 5.6 | 21 | 58.3 |
| Diagnosed with MPX (respondent or someone the respondent knows) | ||||||||||
| No | 26,081 | 79.3 | 20,915 | 80.2 | 2,550 | 9.8 | 2,408 | 9.2 | 208 | 0.8 |
| Yes, only me | 232 | 0.7 | 204 | 87.9 | 7 | 3.0 | 17 | 7.3 | 4 | 1.7 |
| Yes, me and someone I know | 619 | 1.9 | 561 | 90.6 | 23 | 3.7 | 28 | 4.5 | 7 | 1.1 |
| Yes, only someone I know | 3,830 | 11.6 | 3,545 | 92.6 | 117 | 3.1 | 102 | 2.7 | 66 | 1.7 |
| I don’t know | 2,018 | 6.1 | 1,690 | 83.7 | 184 | 9.1 | 122 | 6 | 22 | 1.1 |
| Prefer not to answer | 83 | 0.3 | 53 | 63.9 | 6 | 7.2 | 7 | 8.4 | 17 | 20.5 |
| Missing | 39 | 0.1 | 12 | 30.8 | 3 | 7.7 | 2 | 5.1 | 22 | 56.4 |
| General perception of protection provided by vaccines against diseasese | ||||||||||
| Strongly disagree | 1,293 | 4.0 | 924 | 71.5 | 92 | 7.1 | 270 | 20.9 | 7 | 0.5 |
| Slightly disagree | 702 | 2.2 | 262 | 37.3 | 152 | 21.7 | 280 | 39.9 | 8 | 1.1 |
| Neither disagree nor agree | 951 | 3.0 | 268 | 28.2 | 249 | 26.2 | 406 | 42.7 | 28 | 2.9 |
| Slightly agree | 7,139 | 22.2 | 5,133 | 71.9 | 1,046 | 14.7 | 919 | 12.9 | 41 | 0.6 |
| Strongly agree | 21,590 | 67.3 | 19,651 | 91 | 1,212 | 5.6 | 677 | 3.1 | 50 | 0.2 |
| I don’t know | 401 | 1.2 | 169 | 42.1 | 107 | 26.7 | 85 | 21.2 | 40 | 10.0 |
| Missing | 24 | 0.1 | 8 | 33.3 | 2.0 | 8.3 | 1 | 4.2 | 13 | 54.2 |
| Have you been worried about being treated differently due to monkeypoxe | ||||||||||
| No | 12,245 | 38.1 | 9,363 | 76.5 | 1,228 | 10 | 1,598 | 13.1 | 56 | 0.5 |
| Yes | 11,558 | 36.0 | 10,316 | 89.3 | 749 | 6.5 | 472 | 4.1 | 21 | 0.2 |
| I don’t know | 5,310 | 16.5 | 4,229 | 79.6 | 661 | 12.4 | 394 | 7.4 | 26 | 0.5 |
| Prefer not to answer | 257 | 0.8 | 132 | 51.4 | 38 | 14.8 | 38 | 14.8 | 49 | 19.1 |
| Missing | 2,730 | 8.5 | 2,375 | 87.0 | 184 | 6.7 | 136 | 14.8 | 35 | 1.3 |
| Preferred place to get vaccinatede,f | ||||||||||
| In an STI clinic | 3,399 | 11.1 | 3,012 | 88.6 | 281 | 8.3 | 96 | 2.8 | 10 | 0.3 |
| With my general practitioner | 5,140 | 16.8 | 4,278 | 83.2 | 609 | 11.8 | 233 | 4.5 | 20 | 0.4 |
| In a community-based centre | 1,234 | 4.0 | 1,038 | 84.1 | 153 | 12.4 | 40 | 3.2 | 3 | 0.2 |
| In a vaccination programme centre | 5,493 | 17.9 | 4,645 | 84.6 | 615 | 11.2 | 215 | 3.9 | 18 | 0.3 |
| It doesn’t matter | 14,473 | 47.2 | 13,086 | 90.4 | 950 | 6.6 | 416 | 2.9 | 21 | 0.1 |
| I don’t know | 794 | 2.6 | 297 | 37.4 | 238 | 30 | 188 | 23.7 | 71 | 8.9 |
| Missing | 134 | 0.4 | 59 | 44.0 | 14 | 10.4 | 17 | 12.7 | 44 | 32.8 |
ART: antiretroviral therapy; HIV +: HIV-positive; HIV −: HIV-negative; MPX: monkeypox; PrEP: pre-exposure prophylaxis for HIV; STI: sexually transmitted infection.
a Monkeypox vaccine acceptance and hesitancy were measured as described in the footnote ‘a’ of Table 1.
b The denominator for the percentages is the total sample (n = 32,902), apart from the question related to PrEP (see footnote d) and questions not covered by the Dutch survey (see footnote e). For the PrEP question, the denominator is the number of respondents who did not declare to be HIV + (n = 28,999). For the questions not covered by the Dutch survey, the denominator is 32,100, except for the preferred place of vaccination question (n = 30,667), where the denominator also excluded those who answered ‘I won’t get vaccinated’ to the MPX vaccine acceptance question.
c The percentage is calculated based on the total number of participants in the same sub-category (i.e. second column, on the same line).
d This question was asked only to respondents not declaring to be HIV + (using ART or not) in the previous question.
e These questions were not asked in the Dutch survey.
f This question was asked only to those who did not answer ‘I won’t get vaccinated’ in the MPX vaccine acceptance question.